eCite Digital Repository

GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration

Citation

Riaz, M and Lores-Motta, L and Richardson, AJ and Lu, Y and Montgomery, G and Omar, A and Koenekoop, RK and Chen, J and Muether, P and Altay, L and Schick, T and Fauser, S and Smailhodzic, D and van Asten, F and de Jong, EK and Hoyng, CB and Burdon, KP and MacGregor, S and Guymer, RH and den Hollander, AI and Baird, PN, GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration, Scientific Reports, 6 Article 37924. ISSN 2045-2322 (2016) [Refereed Article]


Preview
PDF
269Kb
  

Copyright Statement

Copyright 2016 the Author(s). Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) https://creativecommons.org/licenses/by/4.0/

DOI: doi:10.1038/srep37924

Abstract

Pooled DNA based GWAS to determine genetic association of SNPs with visual acuity (VA) outcome in anti-vascular endothelial growth factor (anti-VEGF) treated neovascular age-related macular degeneration (nAMD) patients. We performed pooled DNA based GWAS on 285 anti-VEGF treated nAMD patients using high density Illumina 4.3 M array. Primary outcome was change in VA in Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 6 months of anti-VEGF treatment (patients who lost ≥5 ETDRS letters classified as non-responders and all remaining classified as responders). GWAS analysis identified 44 SNPs of interest: 37 with strong evidence of association (p < 9  10-8), 2 in drug resistance genes (p < 5  10-6) and 5 nonsynonymous changes (p < 1  10-4). In the validation phase, individual genotyping of 44 variants showed three SNPs (rs4910623 p = 5.6  10-5, rs323085 p = 6.5  10-4 and rs10198937 p = 1.30  10-3) remained associated with VA response at 6 months. SNP rs4910623 also associated with treatment response at 3 months (p = 1.5  10-3). Replication of these three SNPs in 376 patients revealed association of rs4910623 with poor VA response after 3 and 6 months of treatment (p = 2.4  10-3 and p = 3.5  10-2, respectively). Meta-analysis of both cohorts (673 samples) confirmed association of rs4910623 with poor VA response after 3 months (p = 1.2  10-5) and 6 months (p = 9.3  10-6) of treatment in nAMD patients.

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Ophthalmology and Optometry
Research Field:Ophthalmology
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Hearing, Vision, Speech and Their Disorders
Author:Burdon, KP (Associate Professor Kathryn Burdon)
ID Code:112804
Year Published:2016
Web of Science® Times Cited:2
Deposited By:Menzies Institute for Medical Research
Deposited On:2016-11-30
Last Modified:2017-11-06
Downloads:40 View Download Statistics

Repository Staff Only: item control page